Drug Trial Radar · NCT06135415
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Actual
Start
Dec 21, 2023
Primary completion
Apr 30, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm\^2) and up to 100 cm\^2 in adult participants with actinic keratosis (AK).
Conditions
- Keratosis, Actinic
Interventions
TirbanibulinDrug
Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
Vehicle ointmentOther
Participants will apply vehicle ointment topically on the face or balding scalp with AK.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Lesion Count at Day 57Time frame: Baseline, Day 57
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
Site 17
Augsburg, Germany
Site 1
Bad Bentheim, Germany
Site 3
Bochum, Germany
Site 18
Dresden, Germany
Site 2
Hamburg, Germany
Site 5
Hamburg, Germany
Site 4
Mahlow, Germany
Site 6
Wuppertal, Germany
Site 24
Bari, Italy
Site 25
Bologna, Italy
Site 19
Brescia, Italy
Site 26
Cagliari, Italy
Site 23
Florence, Italy
Site 22
Pisa, Italy
Site 27
Reggio Emilia, Italy
Site 20
Roma, Italy
Site 21
Roma, Italy
Site 7
Roma, Italy
Site 29
Heemstede, Netherlands
Site 28
Maastricht, Netherlands
Site 31
Krakow, Poland
Site 30
Ossy, Poland
Site 10
Warsaw, Poland
Site 11
Warsaw, Poland
Site 9
Warsaw, Poland
Site 8
Wroclaw, Poland
Site 12
Barcelona, Spain
Site 14
Barcelona, Spain
Site 34
Barcelona, Spain
Site 33
Granada, Spain
Site 13
Madrid, Spain
Site 32
Salamanca, Spain
Site 15
Valencia, Spain
Site 35
Valencia, Spain
Site 16
Zaragoza, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.